Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk

Dow Jones

01/16

1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. "We see upside to Wegovy pill consensus sales estimates." Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

January 16, 2026 06:30 ET (11:30 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603960230"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603960230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603960230?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603960230","market":"sg","top_or_hot":-1,"title":"Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1130 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-16 19:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1130 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603960230","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603960230","pubTimestamp":1768563000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股"},"translate_title":"诺和诺德的Wegovy药丸今年销售额可能达到10亿美元——市场讨论","themeId":"d806896b6091b132ff78b81fa73d2804","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96},"content_text":"1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 06:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}